Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with or without tremelimumab plus platinum-etoposide versus platinum-etoposide in first-line extensive-stage small-cell lung cancer
jRCT2080223579Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2017
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of durvalumab, tremelimumab, carboplatin, cisplatin and etoposide in small cell lung cancer (SCLC) (3 arms), sponsored by AstraZeneca. Started Jun 2017; status: completed.
02
Drugs
durvalumabtremelimumabcarboplatincisplatinetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2080223579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223579.